Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1113-1125

  Bajaj, J S ^a   Heuman, D M ^a   Hylemon, P B ^a   Sanyal, A J ^a   Puri, P ^a   Sterling, R K ^a   Luketic, V ^a   Stravitz, R T ^a   Siddiqui, M S ^a   Fuchs, M ^a   Thacker, L R ^a   Wade, J B ^b   Daita, K ^a   Sistrun, S ^a   White, M B ^a   Noble, N A ^a   Thorpe, C ^c   Kakiyama, G ^a   Pandak, W M ^a   Sikaroodi, M ^d   Gillevet, P M ^d   more..

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; BLOOD SAMPLING; CLINICAL ARTICLE; CLOSTRIDIALES; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSBIOSIS; ENDOTOXEMIA; ENTEROBACTERIACEAE; FECES ANALYSIS; FEMALE; FEVER; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE FLORA; LACHNOSPIRACEAE; LACTOBACILLUS RHAMNOSUS; LIVER CIRRHOSIS; MALE; METABOLOMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; RASH; SWELLING; THROAT SWELLING; URINALYSIS;

AGED; DIARRHEA; ENDOTOXEMIA; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HEPATIC ENCEPHALOPATHY; HUMANS; INFLAMMATION; LACTOBACILLUS; LIVER CIRRHOSIS; MALE; METABOLOME; MICROBIOTA; MIDDLE AGED; PROBIOTICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899046306     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12695     Document Type: Article

References (42)

1. Bajaj JS, Hylemon PB, Ridlon JM, et al,. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303: G675-85.
2. Bajaj JS, Ridlon JM, Hylemon PB, et al,. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302: G168-75.
3. Chen Y, Yang F, Lu H, et al,. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54: 562-72.
4. Ortiz M, Jacas C, Cordoba J,. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005; 42 (Suppl. 1): S45-53.
5. Shawcross DL, Wright G, Olde Damink SW, Jalan R,. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007; 22: 125-38.
6. Bajaj JS,. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-47.
7. Hoffman FA, Heimbach JT, Sanders ME, Hibberd PL,. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. Clin Infect Dis 2008; 46 (Suppl. 2): S53-7.
8. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC,. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011; 11: CD008716.
9. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D,. Meta-analysis: lactobacillus GG for treating acute gastroenteritis in children-updated analysis of randomised controlled trials. Aliment Pharmacol Ther 2013; 38: 467-76.
10. Silva M, Jacobus NV, Deneke C, Gorbach SL,. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987; 31: 1231-3.
11. Zocco MA, dal Verme LZ, Cremonini F, et al,. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-74.
12. Bajaj JS, Thacker LR, Heuman DM, et al,. Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study. Liver Transpl 2012; 18: 1179-87.
13. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT,. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
14. Bajaj JS, Hafeezullah M, Franco J, et al,. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008; 135: 1591-600. e1.
15. Bergner M, Bobbitt RA, Carter WB, Gilson BS,. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
16. Gillevet P, Sikaroodi M, Keshavarzian A, Mutlu EA,. Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers 2010; 7: 1065-75.
17. Bajaj JS, Heuman DM, Hylemon PB, et al,. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2013; doi: 10.1016/j.jhep.2013.12.019 [Epub ahead of print].
18. Ahlroos T, Tynkkynen S,. Quantitative strain-specific detection of Lactobacillus rhamnosus GG in human faecal samples by real-time PCR. J Appl Microbiol 2009; 106: 506-14.
19. Kakiyama G, Pandak WM, Gillevet PM, et al,. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949-55.
20. Fiehn O, Barupal DK, Kind T,. Extending biochemical databases by metabolomic surveys. J Biol Chem 2011; 286: 23637-43.
21. Wold S, Sjostrom M, Eriksson L,. PLS-regression: a basic tool for chemometrics. Chemometr Intell Lab Syst 2001; 58: 109-30.
22. White JR, Nagarajan N, Pop M,. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol 2009; 5: e1000352.
23. Naqvi A, Rangwala H, Keshavarzian A, Gillevet P,. Network-based modeling of the human gut microbiome. Chem Biodivers 2010; 7: 1040-50.
24. Shannon P, Markiel A, Ozier O, et al,. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-504.
25. Bajaj JS, Saeian K, Christensen KM, et al,. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-15.
26. Quigley EM, Stanton C, Murphy EF,. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 2013; 58: 1020-7.
27. Besselink MG, van Santvoort HC, Buskens E, et al,. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-9.
28. Bonnel AR, Bunchorntavakul C, Reddy KR,. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9: 727-38.
29. Mangalat N, Liu Y, Fatheree NY, et al,. Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial. PLoS ONE 2012; 7: e43910.
30. Nava GM, Stappenbeck TS,. Diversity of the autochthonous colonic microbiota. Gut Microbes 2011; 2: 99-104.
31. Lebeer S, De Keersmaecker SC, Verhoeven TL, Fadda AA, Marchal K, Vanderleyden J,. Functional analysis of luxS in the probiotic strain Lactobacillus rhamnosus GG reveals a central metabolic role important for growth and biofilm formation. J Bacteriol 2007; 189: 860-71.
32. Douillard FP, Ribbera A, Kant R, et al,. Comparative genomic and functional analysis of 100 Lactobacillus rhamnosus strains and their comparison with strain GG. PLoS Genet 2013; 9: e1003683.
33. Copley SD, Frank E, Kirsch WM, Koch TH,. Detection and possible origins of aminomalonic acid in protein hydrolysates. Anal Biochem 1992; 201: 152-7.
34. Wang Z, Klipfell E, Bennett BJ, et al,. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.
35. Bajaj JS, Heuman DM, Sanyal AJ, et al,. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE 2013; 8: e60042.
36. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK,. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108: 1458-63.
37. Bodiga VL, Boindala S, Putcha U, Subramaniam K, Manchala R,. Chronic low intake of protein or vitamins increases the intestinal epithelial cell apoptosis in Wistar/NIN rats. Nutrition 2005; 21: 949-60.
38. Wang ZT, Yao YM, Xiao GX, Sheng ZY,. The protective effect of supplementation of probiotics combined with riboflavin on the intestinal barrier of the rats after scald injury. Zhonghua Shao Shang Za Zhi 2004; 20: 202-5.
39. Amodio P, Bemeur C, Butterworth R, et al,. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013; 58: 325-36.
40. Yan F, Polk DB,. Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut Microbes 2012; 3: 25-8.
41. Bellot P, Frances R, Such J,. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2012; 33: 31-9.
42. Canganella F, Paganini S, Ovidi M, et al,. A microbiology investigation on probiotic pharmaceutical products used for human health. Microbiol Res 1997; 152: 171-9.